Lexaria Bioscience (LEXX) Non Operating Investment Income (2018 - 2025)
Lexaria Bioscience's (LEXX) quarterly Non Operating Investment Income came in at -$22093.0 in Q4 2025, down 38.67% year-on-year from -$36023.5 in Q4 2024, and down 93.0% quarter-over-quarter from -$11447.0 in Q3 2025.
Lexaria Bioscience (LEXX) Non Operating Investment Income (2018 - 2025) Analysis & Trends
Lexaria Bioscience has disclosed Non Operating Investment Income across 8 years of filings, most recently posting -$22093.0 for Q4 2025.
- Non Operating Investment Income for Q4 2025 came in at -$22093.0, down 38.67% year-over-year; the trailing twelve-month figure through Feb 2026 was -$73915.0 (down 436.2% YoY), and the FY2025 annual result was -$33714.0, up 51.72% from the prior year.
- Non Operating Investment Income came in at -$22093.0 for Q4 2025 at Lexaria Bioscience, down from -$11447.0 in the prior quarter.
- In the past five years, Non Operating Investment Income ranged from a high of $34040.0 in Q1 2025 to a low of -$143918.0 in Q3 2023.
- The 5-year median for Non Operating Investment Income is -$19012.5 (2024), against an average of -$27764.1.
- Across the five-year window, Non Operating Investment Income tumbled 4307.73% in 2021 and surged 862.51% in 2024, its largest moves.
- Lexaria Bioscience's Non Operating Investment Income stood at -$41362.0 in 2021, then slumped by 87.68% to -$77628.0 in 2022, then jumped by 31.45% to -$53215.0 in 2023, then surged by 70.06% to -$15932.0 in 2024, then plunged by 38.67% to -$22093.0 in 2025.
- The last three Non Operating Investment Income figures came in at -$22093.0 (Q4 2025), -$11447.0 (Q3 2025), and -$40375.0 (Q2 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non Operating Investment Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 762,369.55 Bn | 762,369.51 Bn | - | - |
| 2 | Belite Bio | 55,096.00 Bn | 55,096.00 Bn | - | - |
| 3 | Quantum Biopharma | 17,755.80 Bn | 17,755.79 Bn | - | 235,807.00 |
| 4 | Legend Biotech | 3,486.00 Bn | 3,485.71 Bn | 242.10 Mn | - |
| 5 | Akari Therapeutics | 1,737.42 Bn | 1,737.41 Bn | - | 230,000.00 |
| 6 | Evaxion A | 1,551.28 Bn | 1,551.26 Bn | - | - |
| 7 | Psyence Biomedical | 227.32 Bn | 227.31 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 110.84 Bn | 103.59 Bn | 2.59 Bn | - |
| 9 | Abivax | 91.71 Bn | 91.71 Bn | - | - |
| 10 | Lexaria Bioscience | 7.49 Mn | 1.97 Mn | 20,000.00 | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Nov 30, 2025 | -22,093.00 |
| Nov 30, 2025 | -22,093.00 |
| Aug 31, 2025 | -11,447.00 |
| Aug 31, 2025 | -11,447.00 |
| May 31, 2025 | -40,375.00 |
| May 31, 2025 | -40,375.00 |
| Feb 28, 2025 | 34,040.00 |
| Feb 28, 2025 | 34,040.00 |
| Nov 30, 2024 | -15,932.00 |
| Nov 30, 2024 | -15,932.00 |
| Aug 31, 2024 | 9,500.00 |
| Aug 31, 2024 | 9,500.00 |
| May 31, 2024 | -41,393.00 |
| May 31, 2024 | -41,393.00 |
| Feb 29, 2024 | 15,273.00 |
| Feb 29, 2024 | 15,273.00 |
| Nov 30, 2023 | -53,215.00 |
| Nov 30, 2023 | -53,215.00 |
| Aug 31, 2023 | -143,918.00 |
| Aug 31, 2023 | -143,918.00 |